GSK Nov 2024 44.000 call
- Bloomberg
GSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Massive BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Proteg
- Business Wire
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer
- Evening Standard
FTSE 100 Live 3 June: GSK shares tumble, Monzo turns first profit
GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.
